Literature DB >> 18774793

Structure-activity relationships for a novel series of dopamine D2-like receptor ligands based on N-substituted 3-aryl-8-azabicyclo[3.2.1]octan-3-ol.

Noel M Paul1, Michelle Taylor, Rakesh Kumar, Jeffrey R Deschamps, Robert R Luedtke, Amy Hauck Newman.   

Abstract

Discovering dopamine D2-like receptor subtype-selective ligands has been a focus of significant investigation. The D2R-selective antagonist 3-[4-(4-chlorophenyl)-4-hydroxypiperidinyl]methylindole (1, L741,626; K(i)(D2R/D3R) = 11.2:163 nM) has previously provided a lead template for chemical modification. Herein, analogues have been synthesized where the piperidine was replaced by a tropane ring that reversed the selectivity seen in the parent compound, in human hD2(L)R- or hD3R-transfected HEK 293 cells (31, K(i)(D2R/D3R) = 33.4:15.5 nM). Further exploration of both N-substituted and aryl ring-substituted analogues resulted in the discovery of several high affinity D2R/D3R ligands with 3-benzofurylmethyl-substituents (e.g., 45, K(i)(D2R/D3R) = 1.7:0.34 nM) that induced high affinity not achieved in similarly N-substituted piperidine analogues and significantly (470-fold) improved D3R binding affinity compared to the parent ligand 1. X-ray crystallographic data revealed a distinctive spatial arrangement of pharmacophoric elements in the piperidinol vs tropine analogues, providing clues for the diversity in SAR at the D2 and D3 receptor subtypes.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18774793      PMCID: PMC3157365          DOI: 10.1021/jm800532x

Source DB:  PubMed          Journal:  J Med Chem        ISSN: 0022-2623            Impact factor:   7.446


  45 in total

Review 1.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors.

Authors:  J A Ballesteros; L Shi; J A Javitch
Journal:  Mol Pharmacol       Date:  2001-07       Impact factor: 4.436

2.  Design, synthesis, and evaluation of metabolism-based analogues of haloperidol incapable of forming MPP+-like species.

Authors:  M Lyles-Eggleston; R Altundas; J Xia; D M N Sikazwe; P Fan; Q Yang; S Li; W Zhang; X Zhu; A W Schmidt; M Vanase-Frawley; A Shrihkande; A Villalobos; R F Borne; S Y Ablordeppey
Journal:  J Med Chem       Date:  2004-01-29       Impact factor: 7.446

Review 3.  Magic shotguns versus magic bullets: selectively non-selective drugs for mood disorders and schizophrenia.

Authors:  Bryan L Roth; Douglas J Sheffler; Wesley K Kroeze
Journal:  Nat Rev Drug Discov       Date:  2004-04       Impact factor: 84.694

4.  Novel tropane-based irreversible ligands for the dopamine transporter.

Authors:  M F Zou; T Kopajtic; J L Katz; S Wirtz; J B Justice; A H Newman
Journal:  J Med Chem       Date:  2001-12-06       Impact factor: 7.446

Review 5.  Imaging studies on the role of dopamine in cocaine reinforcement and addiction in humans.

Authors:  N D Volkow; J S Fowler; G J Wang
Journal:  J Psychopharmacol       Date:  1999-12       Impact factor: 4.153

6.  Design and synthesis of [(2,3-dichlorophenyl)piperazin-1-yl]alkylfluorenylcarboxamides as novel ligands selective for the dopamine D3 receptor subtype.

Authors:  M J Robarge; S M Husbands; A Kieltyka; R Brodbeck; A Thurkauf; A H Newman
Journal:  J Med Chem       Date:  2001-09-13       Impact factor: 7.446

7.  N-(4-[4-(2,3-dichlorophenyl)piperazin-1-yl]butyl, butenyl and butynyl)arylcarboxamides as novel dopamine D(3) receptor antagonists.

Authors:  Amy Hauck Newman; Jianjing Cao; Christina J Bennett; Michael J Robarge; Rebekah A Freeman; Robert R Luedtke
Journal:  Bioorg Med Chem Lett       Date:  2003-07-07       Impact factor: 2.823

8.  The acute EPS of haloperidol may be unrelated to its metabolic transformation to BCPP+.

Authors:  Donald M N Sikazwe; Shouming Li; Margaret Lyles-Eggleston; Seth Y Ablordeppey
Journal:  Bioorg Med Chem Lett       Date:  2003-11-03       Impact factor: 2.823

9.  S33138 (N-[4-[2-[(3aS,9bR)-8-cyano-1,3a,4,9b-tetrahydro[1] benzopyrano[3,4-c]pyrrol-2(3H)-yl)-ethyl]phenyl-acetamide), a preferential dopamine D3 versus D2 receptor antagonist and potential antipsychotic agent: III. Actions in models of therapeutic activity and induction of side effects.

Authors:  Mark J Millan; Florence Loiseau; Anne Dekeyne; Alain Gobert; Gunnar Flik; Thomas I Cremers; Jean-Michel Rivet; Dorothée Sicard; Rodolphe Billiras; Mauricette Brocco
Journal:  J Pharmacol Exp Ther       Date:  2007-12-20       Impact factor: 4.030

10.  Modulation of selective serotonin reuptake inhibitor and 5-HT1A antagonist activity in 8-aza-bicyclo[3.2.1]octane derivatives of 2,3-dihydro-1,4-benzodioxane.

Authors:  Adam M Gilbert; Gary P Stack; Ramaswamy Nilakantan; Jason Kodah; Megan Tran; Rosemary Scerni; Xiaojie Shi; Deborah L Smith; Terrance H Andree
Journal:  Bioorg Med Chem Lett       Date:  2004-01-19       Impact factor: 2.823

View more
  4 in total

1.  Subtype selectivity of dopamine receptor ligands: insights from structure and ligand-based methods.

Authors:  Qi Wang; Robert H Mach; Robert R Luedtke; David E Reichert
Journal:  J Chem Inf Model       Date:  2010-10-11       Impact factor: 4.956

2.  Synthesis and monoamine transporter affinity of 3alpha-arylmethoxy-3beta-arylnortropanes.

Authors:  Harneet Kaur; Sari Izenwasser; Abha Verma; Dean Wade; Amy Housman; Edwin D Stevens; David L Mobley; Mark L Trudell
Journal:  Bioorg Med Chem Lett       Date:  2009-10-23       Impact factor: 2.823

3.  N-(4-(4-(2,3-dichloro- or 2-methoxyphenyl)piperazin-1-yl)butyl)heterobiarylcarboxamides with functionalized linking chains as high affinity and enantioselective D3 receptor antagonists.

Authors:  Amy Hauck Newman; Peter Grundt; George Cyriac; Jeffrey R Deschamps; Michelle Taylor; Rakesh Kumar; David Ho; Robert R Luedtke
Journal:  J Med Chem       Date:  2009-04-23       Impact factor: 7.446

4.  A New Pathway for the Synthesis of a New Class of Blue Fluorescent Benzofuran Derivatives.

Authors:  Costel Moldoveanu; Ionel Mangalagiu; Dragos Lucian Isac; Anton Airinei; Gheorghita Zbancioc
Journal:  Molecules       Date:  2018-08-06       Impact factor: 4.411

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.